Studies Closed to Enrollment

Thank you for your interest in HVTN 706. The main purpose of this study is to evaluate a vaccine regimen of AD26.Mos4HIV and aluminum phosphate adjuvanted Clade C gp140 and Mosaic gp140 to prevent HIV infection. Currently, Truvada is the only approved medication for PrEP, but early studies with the vaccines have been promising. Researchers do not yet know if this injectable IM vaccine regimen will work to protect people from getting HIV. In this study you will get vaccines every 3 months for 1 year and then be followed for another year and a half.

This study is being offered to 3800 HIV-uninfected cis-gender men and transgender individuals that have sex with cis-gender men and/or transgender individuals who are at increased risk for acquiring HIV infection in Europe, North and Latin America. Before anyone decides whether to join the study, they should learn more about the study, the risks and benefits of participation, and the amount of time involved.

Everyone’s participation is voluntary, and even after deciding to take part in the study, study participants can choose to leave the study at any time.

A description of this study is available at https://clinicaltrials.gov/ct2/show/NCT03964415 as required by US law.

The Principal Investigator is Richard M. Novak MD, Chief of Infectious Diseases, Department of Medicine, University of Illinois at Chicago.

If you are interested in this study, please contact Project WISH at 312-413-5897.

HPTN 083

HPTN 083: Investigational HIV drug

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men (MSM and TGW).

The main purpose of this clinical research trial is to see if cabotegravir, an antiretroviral medication can prevent infection with HIV in persons at high risk for HIV infection.

The study will last 1.5 – 3 years and you may be eligible if you are:

  • 18 years of age or older
  • HIV negative
  • Sex assigned at birth was male
  • Gender – male or trans female
  • Have sex with men

This study is a double-blind study – all participants receive active medication but neither they nor the study staff will be aware of which medication they are getting.  All participants will receive an injection every 2 months and oral tablets that are taken once daily.

Participants will be compensated for their time and will receive regular HIV testing and counseling, condoms and lubricant.

If you are interested in this study – please contact Project WISH to arrange for a phone screen at 312-413-5897

UIC Principal Investigator/s: Richard M. Novak M.D and Stockton Mayer, DO

Study Coordinator: Stephanie Martin, RN, BA

Community Affairs Specialist: Anthony Johnson, MPH

REPRIEVE Randomized Trial to Prevent Vascular Events in HIV

This clinical trial is testing to see if Pitavastatin can prevent heart disease in people with HIV infection who are taking HIV medications. The study is a prospective, double-blind, randomized, placebo-controlled, multicenter phase IV efficacy study.  Participants are randomly assigned to either Pitavastatin or placebo.  Pitavastatin has been approved by the FDA for a different use, to decrease cholesterol.

You may be eligible for REPRIEVE if you:

  • Have HIV and are between the ages of 40 and 75
  • Have been on antiretroviral therapy (ART) for at least 6 months
  • Have no history of cardiovascular disease
  • Are not currently taking a statin drug.

UIC Principal Investigator: Richard M. Novak MD

Study Coordinator: Regina Harden

For more information:

www.reprievetrial.org

www.clinicaltrials.gov

If you are interested in this study – please contact Project WISH to arrange for a phone screen at 312-413-5897

InFLUenza STUDIES

We offer three flu season studies, including a clinical trial of a treatment drug, and observational studies of influenza. If you are a UIH provider and have a patient who currently has flu-like symptoms or confirmed influenza, please call Project WISH at 312-413-5897.

UIC Principal Investigator: Richard M. Novak M.D

Study Coordinator: Marla Schwarber, RN

HVTN 505: HIV Vaccine Study
HVTN 505 is a study evaluating the safety and effectiveness of an HIV vaccine in MSM and transwomen who have sex with men for HIV negative among participants

You may be eligible if you are:
HIV negative
At least 18 years of age

UIC Principal Investigator: Richard M. Novak M.D
Study coordinator: John Stryker NP

GENOCEA: Genital Herpes Vaccine Study
This study is evaluating the safety and efficacy of a therapeutic vaccine for genital herpes (HSV-2) infection that is currently being tested in a clinical trial.

UIC Principal Investigator: Richard M. Novak M.D
Study coordinator: Regina Harden

DRIVE SHIFT STUDY: Investigational HIV drug
This study is evaluating the safety and effectiveness of an investigational medication for HIV-1 among participants who switch from one of several antiretroviral therapies.

You may be eligible if you:
Have HIV and are at least 18 years of age
Have been on a regimen of a Protease inhibitor (PI) and 2 NRTIs
Are interested in switching medication

UIC Principal Investigator: Richard M. Novak MD
Study Coordinator: Regina Harden

DRIVE BEYOND STUDY: Investigational HIV drug
This study is evaluating the safety and efficacy of an investigational medication among participants who have HIV-1 and have not previously taken a treatment medication for HIV.

You may be eligible for this study if you:
Have HIV and are at least 18 years of age
Have lab results that show one of 3 specific HIV genotypes
Are willing to take an investigational medication.

UIC Principal Investigator: Stockton Mayer D.O.
Study Coordinator: Regina Harden

Drive AHEAD STUDY: Investigational HIV drug
The DRIVE AHEAD study is comparing the effectiveness, safety, and tolerability of an investigational HIV drug with an established medication, ATRIPLA.

You may be eligible if you:
Are at least 18 years old
Are HIV-1 positive
Have never take antiretroviral therapy (ART) as treatment for HIV

UIC Principal Investigator: Richard Novak, MD
Study Coordinator: Regina Harden

INSTRUCTIONS: In order to add a sidebar anchor:

  1. Duplicate the existing item, listed as a 1/6 text field. (Or create a 1/6 column and add a text field, modify the class so it’s exactly “additionalAnchor”).
  2. Modify the text field inside the 1/6 column. Inside there, modify the HYPERLINK so that it would go to a corresponding section with a “#” in front of it. (Example, we have a “chief” section on the page, then it would make sense to have the hyperlink go to “#chief”)
  3. Then change the hyperlink TEXT to a appropriate label.
  4. IMPORTANT: If not done already, go into that CONTAINER that corresponds to your anchor (i.e. Meet The Chiefs), and add an ID matching the anchor’s HYPERLINK WITHOUT the “#”, i.e. “chief”.
  5. (If using side bar widget box, then there’s a saved copy of a widget box COLUMN, grab it in the column library, it should 1/6 of a length of a column.)

NOTE: Order added to the sidebar is from last to first.